Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)
| Market Cap | 13.26M-42.3% |
| Revenue (ttm) | 0 |
| Net Income | -57.80M-584.0% |
| EPS | -16.53+34.5% |
| Shares Out | 2.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,085 |
| Open | 3.83 |
| Previous Close | 3.71 |
| Day's Range | 3.82 - 5.20 |
| 52-Week Range | 1.31 - 8.75 |
| Beta | 1.50 |
| Analysts | Buy |
| Price Target | 8.50(+68.32%) |
| Earnings Date | Nov 18, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ADIL
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Latest investor presentation
Next catalysts
- Nov 18, 2026Earnings report
Ask Barron about ADIL
$ADIL stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ADIL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ADIL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ADIL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ADIL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ADIL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ADIL
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $41.73K |
Estimated from each fund’s disclosed top holdings × AUM
ADIL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ADIL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strategic restructuring with leadership appointments and focused pipeline, suggesting management confidence in AT177 development for ulcerative colitis.